- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Aspirin 81mg, Aspirin 162 mg, Aspirin 325mg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 2,098
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Interventions
- Benralizumab Arm A, Benralizumab Arm B, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 138
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 114 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Non-Interventional
- Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 30 Years to 87 Years
- Enrollment
- 1,574 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 40
- States / cities
- Adamsville, Alabama • Foothill Ranch, California • Huntington Beach, California + 37 more
- Conditions
- Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
- Interventions
- Bortezomib, NK cells
- Drug · Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- guideline treatment recommendations
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Boise, Idaho • Seattle, Washington
- Conditions
- Partial-thickness Burn, Ulcer
- Interventions
- NPWT PRO without irrigation, NPWT PRO with irrigation, KCI Ulta
- Device
- Lead sponsor
- Larry Lavery
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive, Heart Failure，Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
- Interventions
- EHR-based Clinician Jumpstart
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Seattle, Washington
- Conditions
- Graft-Versus-Host Disease
- Interventions
- Panobinostat (LBH589)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- COVID-19, Chronic Lung Diseases
- Interventions
- Not listed
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 622 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Seattle, Washington
- Conditions
- Asthma, Asthma Chronic, Asthma Severe Persistent With Exacerbation, Asthma Moderate Persistent With Exacerbation
- Interventions
- PARTICS using a single ICS add on, MART
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 3 more
- Conditions
- COPD
- Interventions
- BGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg, Symbicort® Turbuhaler® (TBH) Inhalation Powder
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 1,902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 63
- States / cities
- Andalusia, Alabama • Jasper, Alabama • Peoria, Arizona + 54 more
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Any T-cell Malignancy, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma, Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Burkett's Lymphoma, Primary Lymphoma of the Central Nervous System
- Interventions
- CDX-1127
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
- Conditions
- Asthma, COPD
- Interventions
- montelukast sodium
- Drug
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Asthma
- Interventions
- Intervention: Budesonide, Usual care: albuterol + systemic steroids
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Year to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- bortezomib, Prednisone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS), SARS CoV 2 Infection, Long COVID19
- Interventions
- To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment, To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA, To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo, To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA, To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo
- Drug · Diagnostic Test
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Smoking Cessation
- Interventions
- placebo, Varenicline Tartarate
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 15 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- QGE031, Omalizumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- BPH, Nocturia, BPH With Urinary Obstruction, Prostatism, Prostate Inflammation
- Interventions
- Microcannula Harvest Adipose, Centricyte 1000, IV Sterile Normal Saline
- Procedure · Device · Biological
- Lead sponsor
- Robert W. Alexander, MD, FICS
- Industry
- Eligibility
- 30 Years to 80 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Stevensville, Montana
- Conditions
- Cancer
- Interventions
- captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Pulmonary Embolism, Pneumonia, Congestive Heart Failure
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- COPD
- Interventions
- AQX-1125, Placebo
- Drug
- Lead sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- ADSCs administration
- Biological
- Lead sponsor
- Arkansas Heart Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas
- Conditions
- Pulmonary Hypertension, Infant, Premature
- Interventions
- Not listed
- Lead sponsor
- Mount Sinai Hospital, Canada
- Other
- Eligibility
- 14 Days and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa